DrugBiological
Anitocabtagene autoleucel clinical trials
Also written CART-ddBCMA.
Keep track of what changes. Save the anitocabtagene autoleucel studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Studies by the year they started
4 studies that test it; most in 2019 (1); 1 more planned to start later
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses anitocabtagene autoleucel is read from its arms, and is right about nine times in ten.
Testing it · 5
- Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related DiseasesRecruitingPhase 1Kite, A Gilead CompanyNCT06626919Written as anito-cel
- A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 3Kite, A Gilead CompanyNCT07887672Written as Anitocabtagene autoleucel
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple MyelomaActive, not recruitingPhase 3Kite, A Gilead CompanyNCT06413498Written as Anitocabtagene Autoleucel
- Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple MyelomaActive, not recruitingPhase 1Kite, A Gilead CompanyNCT04155749Written as anitocabtagene-autoleucel
- Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)Active, not recruitingPhase 2Kite, A Gilead CompanyNCT05396885Written as anitocabtagene-autoleucel
Given in every arm · 1 — anitocabtagene autoleucel is usual care beside what is tested
Codes
What other systems call anitocabtagene autoleucel · ClinicalTrials.gg INT018376
- UNII (FDA) WQD5K35YZTANITOCABTAGENE AUTOLEUCELOne source FDA
- NCI Thesaurus C199003Anitocabtagene AutoleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | WQD5K35YZT | ANITOCABTAGENE AUTOLEUCEL | One source FDA |
| NCI Thesaurus | C199003 | Anitocabtagene Autoleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.